CMS votes to uphold Medicare reimbursement for Cologuard

Listen
Text
  • Small
  • Medium
  • Large

The CMS Advisory Panel on Clinical Diagnostic Laboratory Tests recently held a vote on whether to maintain current Medicare reimbursement for Exact Sciences' Cologuard.

In July, Exact Sciences' chairman and CEO Kevin Conroy presented a proposal to crosswalk Cologuard from its current G-code to a CPT code.

The panel's recent meeting was to determine if the colorectal cancer screening test would maintain its $492.72 reimbursement after crosswalking the code.

The advisory panel unanimously voted to maintain Cologuard's current pricing. The vote was 11 to 0, with one abstention.

"CMS will post a preliminary determination after considering the July meeting comments, today's panel vote and other written comments. A final determination is expected to be released in the November timeframe and will be effective Jan. 1, 2016," said Mr. Conroy.

Copyright © 2021 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.

 

Featured Webinars

Featured Whitepapers

Featured Podcast